Business Context and Reporting Period
Company: SELLAS Life Sciences Group, Inc.
Filing Type: Form 8-K (Current Report)
Date of Report: June 14, 2019 (Event Date: June 18, 2019)
Context: The Company consummated an underwritten public offering of common stock, pre-funded warrants, and accompanying common stock warrants. The offering was conducted pursuant to an Underwriting Agreement with A.G.P./Alliance Global Partners, LLC.
Key Financial Metrics
- Gross Proceeds: Approximately $15 million (before deducting underwriting discounts, commissions, and estimated offering expenses; excludes warrant exercises).
- Offering Price (Common Stock + Warrants): $0.15 per share and warrant.
- Offering Price (Pre-Funded Warrants + Warrants): $0.1499 per pre-funded warrant and warrant.
- Warrant Exercise Price: $0.50 per share for new common stock warrants; $0.0001 per share for pre-funded warrants.
- Debt and Liquidity: The filing text does not provide specific values for existing debt, cash flow, or liquidity positions outside of the new capital raised.
Material Changes and Transaction Details
The Company issued the following securities in the Offering:
- 26,367,200 shares of common stock.
- 73,632,800 pre-funded warrants (issued to purchasers who would otherwise exceed 4.99% beneficial ownership).
- Common stock warrants to purchase up to 100,000,000 shares of common stock.
Material Modifications to Rights: The Company agreed to reduce the exercise price of existing warrants issued on July 16, 2018, to $0.15. Additionally, the Offering triggers adjustments to the exercise price of private placement warrants issued on March 9, 2018, and May 1, 2018. The Company also agreed to seek Nasdaq approval by November 8, 2019, to reduce the exercise price of warrants issued under March 6, 2019 agreements to $0.15.
Outlook, Risks, and Management Commentary
- Warrant Features: New common stock warrants are exercisable immediately, expire in five years, and include anti-dilution protection. They allow for cashless exercise 60 days after issuance if the stock price is below the exercise price.
- Regulatory Status: The registration statement (Form S-1) was declared effective by the SEC on June 13, 2019.
- Risks/Contingencies: The filing does not explicitly detail new risks beyond standard offering terms and the requirement to seek Nasdaq approval for warrant price adjustments.
Investor Verification Checklist
- Verify the net proceeds after deducting underwriting discounts and offering expenses.
- Confirm the specific impact of the warrant exercise price reductions on existing shareholders and dilution.
- Review the full Underwriting Agreement (Exhibit 1.1) and Warrant Agreement (Exhibit 10.1) for covenants and redemption rights.
- Monitor the Company's progress in obtaining Nasdaq approval for the warrant price adjustment by November 8, 2019.